Ano Pharmaceuticals Round C raises nearly $100 million to rapidly advance global research and development of innovative cancer immunological drugs.

Hangzhou, China, In August 2020, Ano Pharmaceuticals, a biopharmaceutical company focused on global research and development of cancer immunotherapy, announced the completion of nearly $100 million in round C financing.
this round of financing is jointly led by Tiger Pharmaceuticals and PCCW Capital, with ATCG Holdings, Shengxin Ventures, Puxin Ruiyuan, Hongtu V and a fund owned by ICBC Capital Global.
founded in Hangzhou, China, in 2016, Ano Pharmaceuticals has a research and development and clinical operations center in New Jersey, USA, and is located as a "global new" oncology drug, facing the global market, participating in global innovation, and its core team comes from the management of the world's top pharmaceutical companies, with extensive product development experience and international perspective.
, Ano Pharma has established an internationally competitive product pipeline covering three clinical stages and several preclinical candidates, and has made significant progress: AN2025 (buparlisib) is an oral pan-PI3K inhibitor for all Class I PI3K subsypes.
in its global Phase 2 clinical trial for head and neck squamous cell carcinoma (HNSCC), patients with a medium survival of up to 10.4 months were awarded the FDA's Fast-Track.
, buparlisib's global multi-center Phase 3 clinical trial for HNSCC has been launched, the first large-scale Phase 3 clinical study conducted worldwide by Ano Pharmaceuticals.
. AN0025 is a highly active and highly selective oral E-type prostate litag 4 (EP4) antagonist with the potential to become a "first in class" tumor immunology drug.
has completed phase 1b clinical trials in Europe and the United States as a new complementary therapy for the treatment of local advanced rectal cancer, data published in ESMO in 2019, and nearly 40 percent of patients have achieved complete pathological remission without surgery or postoperative specimens.
, on the other hand, an American clinical IB phase trial of AN0025 and Mercator KEYTRUDA® for the treatment of a variety of locally advanced/metastasis solid tumors has completed the first patient administration.
. AN1004 (pelareorep) is an intravenously administered lysovirus product with potential for development in a variety of cancer treatments and in combination with chemotherapy and immuno-checkpoint inhibitors.
, has been the first to complete the treatment of breast cancer in Europe and the United States Phase 2 clinical, and the United States FDA "Fast-Track."
open, randomized, multi-center Phase III. clinical trial for the treatment of advanced/metastasis breast cancer with pelareorep is being initiated.
in preclinical studies, Ano Pharma has accumulated a number of preclinical candidates represented by AN4005 (oral PD-L1) and AN3025 (TNFR2 antibodies).
"We are pleased that this financing has been recognized and supported by a number of leading investment institutions in the biopharmaceutical sector, which will further assist our clinical development efforts."
"We look forward to working with investors to accelerate the development of internationally competitive first innovative drugs to address clinically unsolved needs and turn cancer into a non-fatal disease and even a cure," said Lu Yang, Chairman and CEO of Ano Pharmaceuticals.
"China is setting off a wave of innovative drugs, Ano Pharma's strategic vision of global innovation and product pipeline is an important reason for our investment, and we look forward to rapidly advancing the research and development process of Ano Pharmaceutical's clinical stage products through close cooperation between the two sides, so as to bring a new generation of cancer immunotherapy products to the global market as soon as possible," said Dr. Ye Xiaoping, Chairman of Tag Pharmaceuticals.
" About Ano Pharmaceuticals Ano Pharmaceuticals is a clinically-stage global biopharmaceutical company focused on the global development of the first innovative drug, with a focus on being a pioneer in "global new" oncology drugs.
currently, there are three clinically-staged drug candidates, including the FDA fast-track qualified AN2025 (buparlisib) project, which is in the process of global multi-center clinical phase 3; The project, which is launching phase 3 of the Global Multi-Center Clinic, the Global Potential FIC Oncology ImmunoAN0025 (EP4 Antagonist) project, has completed phase 1b clinical trials in Europe and the United States as a new complementary therapy for the treatment of local late-stage rectal cancer, and the European and American Clinical Phase IB trials for the treatment of multiple solid tumors in combination with Keytruda® are under way.
about Tiger Pharma Tyger Pharma was established in 2004 to focus on providing contract research (CRO) professional services throughout the clinical trial process for the development of new drugs.
Teg Pharmaceuticals invests in innovative biopharmaceutical and medical device start-ups by initiating and participating in equity investment funds, providing financial support to start-ups and providing comprehensive research and development solutions for their ongoing projects, such as Ashong Pharmaceuticals, Zerun Bio, Priscing, Tongli Bio, etc.
about PCCW Capital PCCW Capital was established in 2010, is China Securities Investment Fund Association's first filing institutions.
company focused on national strategy, focused on investment in the industry leading enterprises, has invested in more than 60 with core technology, fist products, to fill the gaps of biopharmaceutical enterprises, has become one of the largest number of IPOs in China.
.